Incretin‐based therapies using single agonists towards GLP‐1 receptor (GLP‐1R) or GIP receptor (GIPR) and dual agonists towards GLP‐1R/GIPR have proven to be effective therapeutic options in type 2 diabetes (T2D), obesity, and related CVDs [11, 12]. Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.